Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

5.6K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.6K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

235
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Persistent Ataxia and Atypical Brain Lesions: From the National Multiple Sclerosis Society Case Conference Proceedings.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Scan-wise generalized PET denoising with contrastive adversarial learning.

Physics in medicine and biology·2026
Same author

Imaging Traumatic Brain Injuries in Mice with Potassium Channel PET Tracer [<sup>18</sup>F]3F4AP.

Journal of neurotrauma·2026
Same author

Spinal cord versus brain imaging biomarkers of multiple sclerosis trajectory combining 7T and 3T MRI.

Brain communications·2026
Same author

DNA damage burden causes selective CUX2 neuron loss in neuroinflammation.

Nature·2026

Related Experiment Video

Updated: Sep 12, 2025

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

10.1K

First evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions.

Amal Tiss1, Nara M Michaelson2, Andrew W Russo2

  • 1Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

European Journal of Nuclear Medicine and Molecular Imaging
|August 4, 2025
PubMed
Summary

A new PET tracer, [18F]3F4AP, shows promise for distinguishing multiple sclerosis lesions with varying axonal integrity. This tracer could aid in monitoring disease progression and evaluating new therapies.

Keywords:
Demyelinated axonsMWIMultiple sclerosisPET imagingPotassium channels[18F]3F4AP

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.2K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.0K

Related Experiment Videos

Last Updated: Sep 12, 2025

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

10.1K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.2K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.0K

Area of Science:

  • Neuroimaging
  • Radiochemistry
  • Neurology

Background:

  • Multiple sclerosis (MS) involves demyelination and axonal loss in the central nervous system.
  • Conventional MRI lacks specificity in differentiating MS lesions based on axonal integrity.
  • Novel imaging tracers are needed to assess myelin and axonal status in MS.

Purpose of the Study:

  • To evaluate the potential of [18F]3F4AP, a novel positron emission tomography (PET) tracer, for insights into demyelination in multiple sclerosis.
  • To assess the tracer's ability to distinguish between demyelinated lesions with different axonal integrity.
  • To explore [18F]3F4AP as a tool for monitoring MS progression and therapy response.

Main Methods:

  • Three individuals with MS and three healthy controls underwent dynamic PET scanning with [18F]3F4AP and 3T MRI.
  • MRI sequences included MPRAGE, FLAIR, and Myelin Water Imaging (MWI).
  • Kinetic modeling (2TCM, Logan analysis) was used to assess tracer kinetics, delivery, and binding in brain regions and lesions, comparing PET findings with MRI and myelin content.

Main Results:

  • [18F]3F4AP demonstrated 14% higher accumulation in gray and white matter in MS patients compared to controls.
  • Tracer kinetics were well-described by a two-tissue compartmental model (2TCM), with good correlation between Logan analysis VT and late SUV images.
  • Lesions showed variable tracer binding, suggesting [18F]3F4AP can differentiate lesions with differing axonal integrity, despite similar MRI appearances.

Conclusions:

  • [18F]3F4AP exhibited good reproducibility and identified differences between MS patients and controls.
  • The tracer's heterogeneous binding across lesions indicates its potential to differentiate lesions with and without axonal integrity.
  • [18F]3F4AP may be valuable for monitoring MS progression and evaluating remyelination therapies.